Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

FDA Warned After a Patient Died Following a Fecal Transplant (Stool Transplant)

FDA Warned After a Patient Died Following a Fecal Transplant (Stool Transplant)

The US Food and Drug Administration (FDA), announced on 13 June 2019 that two patients had developed serious infections after fecal transplantation and that one had died because of a stool transplant containing antibiotic-resistant bacteria. Furthermore, the FDA announced that it had halted a number of clinical trials until it could be shown that donated stool was appropriately screened for dangerous microorganisms.

What is fecal transplantation (stool transplantation)?

In medicine, fecal transplantation is the term used for stool / fecal transplantation, a method we have frequently heard about in recent years, whose aim is to support the intestine with a healthy microbiota. Also called fecal microbiota transplantation, it involves administering a solution of fecal matter from a donor into a recipient's intestinal tract to directly change the recipient's intestinal microbial composition and provide a health benefit.

What is microbiota?

Every human is made up of approximately more than 60 trillion cells. About 30 trillion of these are human cells. Around 30 trillion are microorganisms living in the human body. These harmless microorganisms, which may be viruses, bacteria or fungi, are called microbiome / microbiota / flora and are most abundant in the intestine and skin. We continue to live in a mutually beneficial relationship with these useful microorganisms.

Fecal microbiota transplantation is included in gastroenterology treatment guidelines for treating the recurrent form of Clostridium difficile infection, a very serious intestinal disease. Studies also suggest that it may have therapeutic potential for other conditions, such as inflammatory bowel disease, obesity, metabolic syndrome and functional gastrointestinal disorders, but the levels of recommendation and evidence for these are weak. Nevertheless, use is increasing because it is heavily marketed. Fecal transplantation has also become a widely misunderstood medical procedure to which some people attribute miraculous properties; for example, it is persistently recommended for treating a neurodevelopmental condition such as autism despite the absence of scientific evidence.

In some cases, stool transplants have been effective in treating patients with uncontrollable diarrhea. However, this procedure has not been approved by the FDA and is considered experimental and it is stated that its use should remain limited outside certain clinical trials .

The FDA said that the immune systems of both patients who experienced serious problems after fecal transplantation were already compromised at the time of transplantation. The agency said it would not disclose why the patients were immunocompromised, why they received stool transplants, who performed the procedures, or when and where the cases occurred.

Both transplants used fecal matter from the same donor. The report does not specify whether the stool material was delivered as a liquid infusion into the digestive tract through colonoscopy or swallowed as a pill.

Other samples from the same donor were tested after these serious events occurred. The samples were found to contain multidrug-resistant organisms , the same dangerous microbes found in the patients. These were E. coli bacteria resistant to multiple antibiotics and producing an enzyme called extended-spectrum beta-lactamase. The stool had not been tested for microbes before being given to the patients.

The FDA issued a warning to researchers, stating that stool collected from donors in stool transplantation studies must be screened for drug-resistant microbes. It also warned that fecal transplantation may be risky, is not FDA-approved, and should be used only as a last resort when C. difficile infection does not respond to standard treatments.

Sources

1. Fecal Transplant Is Linked to a Patient’s Death, the F.D.A. Warns.
https://www.nytimes.com - 13 June 2019.

2. FDA In Brief: FDA warns about potential risk of serious infections caused by multi-drug resistant organisms related to the investigational use of Fecal Microbiota for Transplantation.
fda.gov - 13 June 2019.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

FDA Warned After a Patient Died Following a Fecal Transplant (Stool Transplant)

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy